Alaunos Therapeutics, Inc.
$2.84
▼
-2.01%
2026-04-21 09:45:00
www.alaunos.com
NCM: TCRT
Explore Alaunos Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.71 M
Current Price
$2.84
52W High / Low
$6.2 / $1.67
Stock P/E
—
Book Value
$1.27
Dividend Yield
—
ROCE
-233.25%
ROE
-1.98%
Face Value
—
EPS
$-2.2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1
Beta
-1.13
Debt / Equity
—
Current Ratio
2.44
Quick Ratio
2.45
Forward P/E
-4.82
Price / Sales
1,290
Enterprise Value
$5.49 M
EV / EBITDA
-1.3
EV / Revenue
1,097.63
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arcutis Biotherapeutics, Inc. | $24.47 | — | $3.04 B | — | -4.03% | -9.3% | $31.77 / $12.42 | $1.54 |
| 2. | Shattuck Labs, Inc. | $7.88 | — | $538.88 M | — | -61.34% | -60.25% | $7.68 / $0.71 | $1.3 |
| 3. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 4. | Bicara Therapeutics Inc. | $23.47 | — | $1.57 B | — | -38.7% | -30.89% | $24.25 / $7.8 | $7.37 |
| 5. | BiomX Inc. | $1.46 | — | $9.55 M | — | -101.67% | -3.17% | $14.71 / $1.5 | $-12.5 |
| 6. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 7. | Galectin Therapeutics Inc. | $2.29 | — | $156.67 M | — | -174.62% | 26.9% | $7.13 / $1.21 | $-1.97 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -0.91 M | -1.19 M | -1.04 M | -1.09 M | -0.76 M | — |
| Net Profit | -0.89 M | -1.16 M | -1.05 M | -1.07 M | -0.74 M | — |
| EPS in Rs | -0.4 | -0.52 | -0.47 | -0.48 | -0.33 | -0.7 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.01 M | 0.01 M | 0.01 M | 2.92 M |
| Operating Profit | -4.22 M | -4.81 M | -28.49 M | -35.24 M |
| Net Profit | -4.18 M | -4.68 M | -35.14 M | -37.73 M |
| EPS in Rs | -1.87 | -2.1 | -15.74 | -16.91 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.97 M | 2.75 M | 8.26 M | 64.94 M |
| Total Liabilities | 0.81 M | 0.69 M | 1.96 M | 26.38 M |
| Equity | 2.15 M | 2.06 M | 6.31 M | 38.55 M |
| Current Assets | 1.99 M | 2.75 M | 8.26 M | 53.8 M |
| Current Liabilities | 0.81 M | 0.69 M | 1.96 M | 24.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -2.87 M | -4.97 M | -30.14 M | -29.23 M |
| Investing CF | -0.1 M | 0 M | 1.35 M | -0.19 M |
| Financing CF | 3.26 M | 0 M | -18.14 M | 6.37 M |
| Free CF | -2.97 M | -4.97 M | -30.34 M | -29.45 M |
| Capex | -0.1 M | — | -0.2 M | -0.22 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 100% | -99.83% | — | — |
| Earnings Growth % | 86.68% | 6.86% | — | — |
| Profit Margin % | -46790% | -702800% | -1291.24% | — |
| Operating Margin % | -48120% | -569860% | -1205.95% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -48100% | -618080% | -1088.88% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-07-18 | 1:0.1 |
| 2024-02-01 | 1:0.0666667 |